# RECEIVED

SEP 2 0 2000

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

Group Art Unit: 164

Examiner: V. Portner

In re application of:

Dario NERI et al.

Serial No.: 09/512,082

Filed: February 24, 2000

SPECIFIC BINDING MOLECULES FOR SCINTIGRAPHY, For:

CONJUGATES CONTAINING THEM AND THERAPEUTIC METHOD

FOR TREATMENT OF ANGIOGENESIS

#### REPLY

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

In response to the Office Action dated August 21, 2000, please amend the aboveidentified application as indicated below and consider the Remarks which follow:

### IN THE SPECIFICATION:

After the title, please add:

#### **RELATED APPLICATIONS:**

-- This application is a Continuation-in-Part of U.S. application no: 09/075,338, filed May 11, 1998, which is a Continuation-in-Part of U.S. application no: 09/300,425, filed April 28, 1999, both of which are herein incorporated by reference in their entirety.--

#### IN THE CLAIMS:

Please cancel claims 1-13 and 18 without prejudice or disclaimer.

#### REMARKS

#### **Small Entity Status**

Please note that this application is no longer entitled to Small Entity Status.

#### Oath/Declaration

Applicants wish to clarify that the claims to priority to two ancestor U.S. applications should have been made under 35 U.S.C. 120. Claiming them under 35 U.S.C. 119 was incorrect. A corrected Supplemental Declaration will be filed shortly.

## Sequence Listing

A Sequence Listing was filed on September 1, 2000.

# Objection to the Specification

Applicant could find nothing in the M.P.E.P. that indicates reference to a world wide web (www) site is improper, and therefore have not amended the specification on Page 15 as suggested in the Office Action.

#### The restriction requirement

Applicants elect the claims of Group IV (claims 20-34), with traverse. The traverse is based, in part, on the fact that the subject matter of the claims of Group IV is related to that of the other claims in the application. Therefore, a search of all the claims in the application would not be an undue burden on the Examiner. If the search and examination can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions. See, e.g., M.P.E.P. 803.

Applicants note an apparent error in Group III, *i.e.*, claims 25 and 27 are also included in Group IV. Applicants request that the <u>only</u> remaining claim in Group III, claim 19, also be examined with the elected claims, because the subject matter (at least as it relates to a method of therapy) overlaps with that of the claims of Group IV.

SE 20 2000

TECH CENTER 1600/2900

Since claims 1-13 and 18 are being examined in ancestor application no: 09/075,338, these claims have been canceled without prejudice in the instant application.

Respectfully submitted,

Namer Axeland (fra. 14.47) fr Richard M. Lebovitz (Reg. No. 37,067)

Attorneys for Applicants

Nancy J. Axelrod (Reg. No. 44,014)

Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I 2200 Clarendon Boulevard, Suite 1400 Arlington, Virginia 22201

(703) 812-5304

E-mail address: axelrod@mwzb.com

Filed: September 18, 2000

RML/NJA/lvb K:\PAT\Sch\1733p2\reply 9-18-00.wpd